290 related articles for article (PubMed ID: 34724091)
1. Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.
Li H; Wu M; Wu Z; Liang J; Wang L; Yang X; Lin Z; Li J
Cancer Immunol Immunother; 2022 Jun; 71(6):1519-1530. PubMed ID: 34724091
[TBL] [Abstract][Full Text] [Related]
2. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
Ma R; Tang Z; Wang J
J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
[TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
6. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
8. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
[TBL] [Abstract][Full Text] [Related]
9. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
11. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble interleukin-2 receptor alpha levels in patients with gynecologic cancers: early effect of surgery.
Barton DP; Blanchard DK; Michelini-Norris B; Roberts WS; Hoffman MS; Fiorica JV; Nicosia SV; Cavanagh D; Djeu JY
Am J Reprod Immunol; 1993; 30(2-3):202-6. PubMed ID: 8311929
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Tozuka T; Yanagitani N; Yoshida H; Manabe R; Ogusu S; Tsugitomi R; Sakamoto H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
Invest New Drugs; 2023 Jun; 41(3):411-420. PubMed ID: 37058183
[TBL] [Abstract][Full Text] [Related]
14. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
15. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
17. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
18. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
19. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
[TBL] [Abstract][Full Text] [Related]
20. High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer.
Deng Y; Liu L; Feng W; Lin Z; Ning Y; Luo X
Recent Pat Anticancer Drug Discov; 2021; 16(4):533-539. PubMed ID: 34551701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]